Who are ibalizumab-uiyk's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trogarzo, Anti-Thymocyte Globulins, Individual ATG, Thymoglobulin (ATG), Thymoglobuline Genzyme, ATG.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibalizumab-uiyk.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ibalizumab-uiyk — Competitive Intelligence Brief

ibalizumab-uiyk (ibalizumab-uiyk) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD4 receptor antagonist. Area: Infectious Disease.

phase 3 CD4 receptor antagonist CD4 Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

ibalizumab-uiyk (ibalizumab-uiyk) — TaiMed Biologics Inc.. Ibalizumab-uiyk is a monoclonal antibody that binds to the CD4 receptor on T cells, preventing HIV entry and replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ibalizumab-uiyk TARGET	ibalizumab-uiyk	TaiMed Biologics Inc.	phase 3	CD4 receptor antagonist	CD4
Trogarzo	IBALIZUMAB	Taimed Biologics Usa	marketed	CD4-directed Blocking Antibody [EPC]	T-cell surface glycoprotein CD4	2018-01-01
Anti-Thymocyte Globulins	Anti-Thymocyte Globulins	Tianjin First Central Hospital	marketed	Polyclonal antibody; immunosuppressant	T lymphocyte surface antigens (CD2, CD3, CD4, CD8, and other T cell markers)
Individual ATG	Individual ATG	The First Affiliated Hospital of Soochow University	marketed	Polyclonal antithymocyte globulin (immunosuppressant)	T lymphocytes (CD2, CD3, CD4, CD8, CD25 antigens)
Thymoglobulin (ATG)	Thymoglobulin (ATG)	M.D. Anderson Cancer Center	marketed	Polyclonal antithymocyte globulin (ATG)	Multiple T-cell antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR)
Thymoglobuline Genzyme	Thymoglobuline Genzyme	University Hospital, Basel, Switzerland	marketed	Polyclonal antithymocyte globulin (ATG)	Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR, and others)
ATG	ATG	ITB-Med LLC	marketed	Polyclonal antithymocyte antibody	T-cell surface antigens (CD2, CD3, CD4, CD8, and other T-cell markers)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD4 receptor antagonist class)

Breath of Life International Pharma Ltd · 1 drug in this class
TaiMed Biologics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ibalizumab-uiyk — Competitive Intelligence Brief. https://druglandscape.com/ci/ibalizumab-uiyk. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab